U.S. Markets closed

Patrys Limited (PAB.AX)

ASX - ASX Delayed Price. Currency in AUD
Add to watchlist
0.021-0.001 (-4.545%)
At close: 4:10PM AEST

Patrys Limited

100 Albert Road
Level 4
South Melbourne, VIC 3205
61 3 9692 7222

Full Time Employees

Key Executives

Dr. James A. Campbell Ph.D., MBAMD, CEO & Director300kN/AN/A
Ms. Melanie Jaye LeydinCompany Sec.96kN/A44
Dr. Deanne Greenwood Ph.D., MBA, GAICDVP of Bus. Devel. & Intellectual PropertyN/AN/AN/A
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


Patrys Limited, a biopharmaceutical company, develops products for the treatment of cancer in Australia. The company develops PAT-SM6, a natural human antibody that is in Phase I/IIa clinical trials used for the treatment of various types of cancer, including solid tumors, such as melanoma, breast, colon, and pancreatic, as well as blood-based cancers, such as multiple myeloma; and PAT-SC1, a clinical trial antibody that treats gastric cancer. It also develops PAT-LM1, a natural human antibody that is used for the treatment of colon, lung, breast, ovary, and pancreatic cancers; and Deoxymab 3E10, a lupus autoantibody that penetrates live cell nuclei by binding to DNA or its precursors outside of cells and then following it into cell nuclei through a nucleoside transporter. The company was founded in 2006 and is based in South Melbourne, Australia.

Corporate Governance

Patrys Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.